Intended for healthcare professionals

Letters Molnupiravir’s premature authorisation

Molnupiravir’s authorisation should be re-evaluated after the Panoramic trial is reported

BMJ 2022; 377 doi: (Published 26 April 2022) Cite this as: BMJ 2022;377:o973
  1. Andrew Hill, senior visiting research fellow
  1. Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GF, UK
  1. andrewhillmv{at}

Brophy’s editorial on Merck’s Move-Out trial of molnupiravir raises important concerns about the approval of molnupiravir to treat outpatients with covid-19 in the United Kingdom.1 Molnupiravir has not yet been approved in Europe,2 and orders were recently cancelled in France.3

Molnupiravir reduced the risk of hospital admission or death by 52% versus placebo in the interim analysis but raised risk by 35% among patients subsequently evaluated.4 There was no clear explanation …

View Full Text

Log in

Log in through your institution


* For online subscription